Baicalein Safety and Regulatory Status: Toxicology, Use Boundaries, and Compliance in Three Major Markets

Part of Baicalein Complete GuideHerb Wiki Editorial TeamCAS 491-67-8Last updated 2026-10-20

Definition in One Sentence

Baicalein (CAS 491-67-8) is the flavone aglycone in Scutellaria root. Existing toxicological data are mainly from animal experiments—low acute toxicity but lacking long-term human safety data; its compliance status depends on three variables: form (extract or isolate), use (food / health food / cosmetics / drugs / feed), and target market. Any change can alter the conclusion.

Toxicology Data: What Exists, What Is Missing

What exists

ItemCurrent understandingEvidence strength
Acute toxicityHigh animal oral tolerance; LD50 reported at grams per kilogramAnimal, fairly consistent
Subchronic toxicityRepeated-dose studies show no clear target-organ damage; liver-enzyme fluctuations at high dosesAnimal, limited
GenotoxicityMostly negative Ames test reportsIn vitro, fairly consistent
Reproductive and developmental toxicitySystematic research lackingInsufficient
Human safetyMostly small-sample, short-term studies, mostly Scutellaria-containing formulas rather than the isolateWeak
Long-term high doseNo systematic dataMissing

What is missing is more noteworthy: no long-term human data, no child or pregnant-woman data, no data for people with impaired liver or kidney function, and no systematic research on co-use with other common supplements. So the correct statement is "no obvious safety problems observed under existing evidence," not "safe."

A traditional basis easily misused: Scutellaria is used in TCM to prevent miscarriage; this is experience at the herb and formula level. Inferring that "baicalein isolate is safe during pregnancy" is an invalid deduction—the isolate has high purity and different dose and exposure routes, so safety conclusions cannot be transferred.

Four Categories of Risk That Truly Deserve Attention

2.1 Metabolic Drug Interactions

After oral administration, baicalein is rapidly handled by phase II metabolism (glucuronidation, sulfation) in the intestinal wall and liver, and studies also show it affects some metabolic enzymes and transporters. Practical implications:

  • Co-use with drugs also metabolized by glucuronidation may alter each other's exposure;
  • co-use with narrow-therapeutic-window drugs (e.g., some anticoagulants, immunosuppressants, antineoplastics) requires professional evaluation;
  • in vitro inhibition data cannot be directly extrapolated to humans, but is sufficient to support the caution that co-use requires care.

This is the most realistic safety issue for baicalein and the key point labels should warn about.

2.2 Liver

High dose, long term, and multi-ingredient co-use are the main sources of uncertainty. The literature has sporadic reports of transaminase elevation, but mostly in formula and multi-factor contexts, making causality hard to establish. The reasonable approach: advise users to consult a physician before long-term use and to discontinue if discomfort occurs; the product side should not claim disease-related effects such as "liver protection."

2.3 Topical Use and Cosmetics

  • Contact dermatitis: individual case reports of botanical flavone raw materials exist; patch testing is a routine risk-control measure;
  • Oxidative discoloration: baicalein oxidizes in light and air; as color deepens, more irritating products may form, so formulations need antioxidant and light-protective design;
  • Incompatibility: co-use with raw materials containing multivalent metal ions such as iron and aluminum may complex and discolor, requiring compatibility testing.

2.4 Special Populations

PopulationRecommended wording
Pregnant and lactatingNo safety data; high-dose supplements not recommended
ChildrenNo dose-safety data; not recommended
Impaired liver/kidney functionMetabolism and clearance may change; physician evaluation needed
PerioperativeAffects metabolic enzymes; recommend discontinuation before surgery (specific period per physician)
Currently on medicationPossible interaction; consult physician or pharmacist before use

China: Four Distinct Regulatory Lines

Three-market regulation
Fig. 1 Comparison of the three regulatory pathways in China, EU, and US (food supplement / herbal product / cosmetic raw material). Placeholder image, to be replaced with a real/illustrated asset.

This is the easiest place to err. For the same substance, different uses mean completely different authorities and rules.

UseRegulatory basisStatus of Scutellaria / baicalein
Herb and decoction piecesChinese Pharmacopoeia 2025 edition, Scutellaria monographOfficial drug standard: baicalin ≥9.0%, moisture ≤12.0%, total ash ≤6.0%, extractables ≥40.0% in the monograph; SO₂, heavy metals, and pesticide residues in Volume IV general chapters
Health foodHealth-food raw-material and function catalog managementScutellaria is listed in the former MOH "List of Items Usable in Health Food" (Wei Fa Jian [2002] No. 51, Annex 2), usable in health food
CosmeticsCosmetic Supervision and Administration Regulation and Inventory of Existing Cosmetic IngredientsRecorded under standard names such as Scutellaria baicalensis root extract, used per filed efficacy claims
Ordinary foodFood-medicine substance catalogNot listed; not usable in ordinary food; may not claim "food grade"
Drug (isolate)Drug registration managementBaicalein as API or drug-ingredient must be registered via the drug pathway; food-grade extract cannot substitute
Feed and veterinary drugsFeed raw-material catalog, veterinary drug managementFollow catalog and product provisions; verify item by item

"Not in the food-medicine substance catalog" and "usable in health food" both hold because they follow two different management paths: the former governs "whether it can be eaten as ordinary food," the latter "whether it can be a health-food raw material." When these two statements seem conflicting, do not rush to judge which is wrong; first see which line is being discussed.

Health-function claims: the currently permitted health functions have a clear catalog (24 items); functions not in the catalog may not be claimed. Antioxidant is claimable, but "anti-tumor," "liver protection," "blood-sugar lowering," etc., are disease-treatment or unapproved functions and must never be used.

EU: Form Determines the Pathway

Form / usePathwayKey point
CosmeticsEU Cosmetics Regulation (EC) No 1223/2009Scutellaria baicalensis root extract is listed in CosIng; CPSR safety assessment and PIF required
Food supplement (root extract)Member-state food law + Novel Food assessmentTraditional use differs by country; confirm with the target member state
High-purity baicalein isolateUsually treated as Novel FoodAuthorization required before use as a food ingredient; long process, high cost
Herbal productMember-state traditional-herbal-medicine registration pathwayPer each country's pharmaceutical requirements; not a unified pathway

The easiest pitfall: assuming "if the extract sells, the isolate sells too." In the EU, a leap in purity and process changes the legal nature—the same plant's crude extract may be a traditional food, while the 98% isolate may be an unauthorized novel-food ingredient.

US: Supplement Framework, but with Preconditions

  • Dietary supplement: Scutellaria root is a dietary ingredient already in use before 1994 and generally qualifies as a supplement raw material under the DSHEA framework; but a new process, an extract that changes the compositional profile, or a high-purity isolate may constitute a "new dietary ingredient," requiring an NDI notification.
  • Ordinary food and beverages: not a permitted food additive; may not be used as a food component; related "food additive" claims carry high risk.
  • Drugs: no FDA-approved isolate drug exists; any therapeutic claim would reclassify the product as an unapproved new drug.
  • Structure/function claims: limited structure-function claims are allowed, but must carry a disclaimer and must not involve disease.

Export Practice: Three Questions You Must Answer

Any compliance judgment starts with these three questions; without any one of them, no conclusion can be given:

  1. What is the form? Root extract (standardized to a certain content) / baicalin / baicalein isolate (90% or 98%).
  2. What is the use? Food, food supplement, cosmetics, drug, feed, research reagent.
  3. Which market? China, EU (which member state), US, Japan, Southeast Asia.

Only after answering the three questions do you discuss test items, label text, and registration pathways. Conversely, doing tests first and asking about use later usually means redoing them.

Claim Boundary: What Can and Cannot Be Said

ScenarioCan sayCannot say
CosmeticsSoothing, antioxidant, oil-control, and other filed-efficacy functionsAcne-treatment, anti-inflammatory drug effect, barrier-disease repair
Health foodFunctions permitted in the catalog (e.g., antioxidant)Anti-tumor, blood-sugar lowering, liver protection, immune enhancement (unapproved)
Raw-material sales materialsIn vitro and animal study results, mechanism pathways, literature sources"Clinically proven," "cures," "replaces drugs"
Research reagentFor research only, not for human useAny wording implying edibility

A practical principle: anything that can be written as "studies show… (in vitro / animal)" may be written; anything that needs to say "can treat…" must never be written. Hold this line and most regulatory risk is avoided.

Accompanying Document Package

A complete raw-material safety document package should contain:

  1. COA (assay, related substances, moisture, ash, heavy metals four items, microorganisms, residual solvents);
  2. MSDS / SDS (in the target-market format, GHS classification);
  3. Specification sheet (including test method and calculation basis);
  4. Stability data (accelerated and long-term, supporting the retest period);
  5. Non-GMO statement, allergen statement, non-irradiation statement (often required for export);
  6. Certificate of origin and manufacturer qualifications (business license, production permit);
  7. Method validation summary (especially important for isolate specifications, as there is no pharmacopoeial method).

Frequently Asked Questions

Q1: Is baicalein safe?

Under existing evidence, acute toxicity is low and animal experiments show no clear target-organ damage; but long-term human data are lacking. The proper statement is "no obvious safety problems observed at recommended dosage," not "absolutely safe."

Q2: Scutellaria is not in the food-medicine substance catalog; why can it be used in health food?

Two different management lines. The food-medicine substance catalog governs "whether it can be used in ordinary food," the health-food raw-material list governs "whether it can be used in health food." Scutellaria is within the latter but not the former.

Q3: Can baicalein be used in ordinary food or beverages?

Not in the Chinese market. The EU and US are stricter on high-purity isolates, usually treating them as novel-food ingredients.

Q4: Can pregnant women take supplements containing baicalein?

Not recommended. The "miscarriage-prevention" experience at the herbal-medicine level cannot be extended to the isolate, and pregnancy safety data are lacking.

Q5: Does baicalein interact with drugs?

It is possible, mainly involving phase II metabolic pathways. People taking narrow-therapeutic-window drugs should consult a physician or pharmacist before use.

Q6: What should be noted when using baicalein in cosmetics?

Standard raw-material name, filed-efficacy scope, patch testing, antioxidant and light-protective packaging, and compatibility with metal-ion raw materials.

Q7: What is needed to export to the EU?

First determine form and use: cosmetics follow CPSR and PIF; food supplements confirm member state and traditional use; high-purity isolates usually need Novel Food authorization.

Q8: Can one claim "natural antibiotic" or "plant anti-inflammatory drug"?

No. Such wording involves both disease-treatment claims and the definition of a drug, making it a high-risk claim.

Q9: Are MSDS and COA the same thing?

No. The COA states the quality data of this batch; the MSDS states the substance's hazards and safe-handling requirements. Their uses differ, and both are usually needed for export.

Q10: Do regulations change?

Yes, and faster than standards. Catalog additions, function-claim adjustments, and assessment-conclusion updates all affect the conclusion; the latest texts must be checked before signing contracts and filing.

References and Search Suggestions

  1. Chinese Pharmacopoeia Commission. Chinese Pharmacopoeia (2025 edition, Volume I), "Scutellaria" monograph.
  2. Ministry of Health. Notice on Further Regulating the Management of Health-Food Raw Materials (Wei Fa Jian [2002] No. 51), Annex 2 "List of Items Usable in Health Food."
  3. National Medical Products Administration. Safety and Technical Standards for Cosmetics (current edition) and Inventory of Existing Cosmetic Ingredients.
  4. Baicalein toxicology and safety: PubMed search baicalein AND (toxicity OR safety OR pharmacokinetics OR interaction).
  5. EU Novel Food catalog and US FDA NDI-related guidance (follow the official latest text).

The 4th item gives a search path rather than specific citations; follow this search to verify when the original is needed; regulatory provisions follow the currently valid version.

Disclaimer

This article is raw-material safety and regulatory information for R&D, registration, procurement, and quality personnel; it does not constitute medical advice, medication guidance, or legal/compliance opinion. The toxicology conclusions herein are based on public research; the regulatory status changes with revisions. Actual production, sales, and filings should follow the latest provisions of the competent authority, the target-market regulations, and professional legal advice.